Date | Title | Description | |
---|---|---|---|
22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
03 Nov 2021 | On buy-back programmes | The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. | Download |
16 Jul 2021 | On Corporate Governance | ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company | Download |
22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
29 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 22 September and 28 September 2023 | Download |
22 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 September and 21 September 2023 | Download |
15 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 8 September and 14 September 2023 | Download |
08 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 1 September and 7 September 2023 | Download |
01 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 25 August and 31 August 2023 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |